Shilpa Medicare Limited (SHILPAMED) Fair Value & Analysis
Healthcare · IN · Market cap ₹118B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +18.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹267.00 – ₹608.95 · fair‑value band ₹173.91 – ₹310.81 · the ₹608.95 price screens above the ₹242.36 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shilpa Medicare Limited (SHILPAMED) currently trades at ₹608.95, while our model-based Fair Value estimate is ₹242.36 — implying the stock looks roughly 60.2% overvalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Shilpa Medicare Limited generated revenue of ₹15.4B at a net margin of 15.8%. Revenue grew 31.5% year over year. It earns a return on equity of 9.8%. Net debt stands at ₹6.1B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Shilpa Medicare Limited reported revenue of ₹15.4B in FY2026 versus ₹11.4B in FY2022, a compound +7.8%/yr. Reported net income was ₹2.4B in FY2026, compounding +41.5%/yr from FY2022.
Is SHILPAMED fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shilpa Medicare Limited (SHILPAMED) undervalued?
What is the fair value of SHILPAMED?
What is the quality score of SHILPAMED?
What is the revenue of Shilpa Medicare Limited (SHILPAMED)?
What is the net profit margin of SHILPAMED?
Does Shilpa Medicare Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.